Phoenix Molecular Designs
Founded 2012 · 11 employees on LinkedIn · 3 known investors
Phoenix Molecular Designs (PhoenixMD) is a biotechnology company developing targeted breast cancer therapeutics, including PMD-026, a first-in-class RSK2 inhibitor in Phase 2 clinical trials paired with a companion diagnostic. The company applies medicinal chemistry, computational modeling, and cancer biology to treat breast cancer and other cancers.
Also known as PhoenixMD
Founders & leadership
Phoenix Molecular Designs was founded in 2012 by Sandra Dunn.
Investors · 3
Company profile
researched Aug 2026Phoenix Molecular Designs (PhoenixMD) is a biotechnology company focused on the design of precise cancer therapeutics. Its work centers on developing novel drugs that target RSK, a kinase the company describes as a driver of cancerous tumor growth and metastasis that has historically been considered undruggable.
The company positions its programs around personalized and alternative cancer therapeutics intended to preserve patient quality of life. Its lead compound, PMD-026, is discussed in oncology trade coverage in the context of RSK-driven breast cancer, a patient group described as having had limited treatment options.
Latest developments
An OncLive feature covered the science behind PMD-026 and its potential in RSK-driven breast cancer, with commentary from Dr. Hung Khong of Banner MD Anderson Cancer Center on RSK inhibition in RSK-high, CDK4/6 inhibitor-resistant breast cancer.
▸Full profile — market position, technology, go-to-market
Market position
The company presents itself as working on a target, RSK, that has not previously been successfully drugged, addressing RSK-driven breast cancer where treatment options have been limited.
Technology
The company's technology is directed at pharmacological inhibition of RSK, a target it characterizes as previously undruggable, with the aim of blocking a driver of tumor growth and metastasis. PMD-026 is the compound associated with this approach.
Go-to-market
Patients with cancer, and specifically patients with RSK-driven breast cancer, together with the oncologists and cancer centers treating them.
Compiled by commissioned research from 1 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
▸Research sources · 1
primary sources listed
- Phoenix Molecular Designsphoenixmd.ca · web
1 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Phoenix Molecular Designs do?
- Biotechnology company designing precise cancer therapeutics targeting RSK, a driver of tumor growth and metastasis.
- Who founded Phoenix Molecular Designs?
- Phoenix Molecular Designs was founded by Sandra Dunn in 2012.
- Who are Phoenix Molecular Designs's investors?
- Phoenix Molecular Designs's investors include Eshelman Ventures, LLC, Flucas Ventures, Pallasite Ventures.